期刊文献+

盐酸美金刚缓释微丸的制备及体外释放度考察 被引量:6

Preparation and Release Behavior in vitro of Memantine Hydrochloride Sustained-release Pellets
下载PDF
导出
摘要 目的:制备盐酸美金刚缓释微丸,并对其体外释放度进行考察。方法:采用流化床包衣法制备盐酸美金刚载药微丸,再用Eudragit RL 30D和Eudragit RS 30D进行包衣,制成盐酸美金刚缓释微丸,并考察盐酸美金刚缓释微丸的体外释药行为。结果:体外释放度试验显示,制备的盐酸美金刚缓释微丸在24 h内平稳释放且释药完全,释药规律符合零级释药模型。结论:用本方法制备的盐酸美金刚缓释微丸具有缓释效果。 Objective: To prepare sustained-release pellets of memantine hydrochloride and investigate the in vitro drug release behavior. Methods: The drug-loaded pellets were prepared by a fluid bed coating technology,the sustained-release pellets were prepared with Eudragit RL 30 D and Eudragit RS 30 D as the coating materials,and in vitro drug release behavior of the sustained-release pellets was studied. Results: The in vitro drug release was steady and complete in 24 h,which fit a zero-order kinetics model. Conclusion:The memantine hydrochloride sustained-release pellets has the sustained-release property.
出处 《中国药师》 CAS 2015年第2期233-237,共5页 China Pharmacist
关键词 盐酸美金刚 缓释微丸 丙烯酸树脂 零级释药模型 Memantine hydrochloride Sustained-release pellets Polyacrylic acid resin Zero-order kinetics model
  • 相关文献

参考文献6

  • 1罗京京,何玲,刘国卿.治疗阿尔茨海默病新药盐酸美金刚[J].中国新药杂志,2006,15(9):742-744. 被引量:24
  • 2Farlow MR. NMDA receptor antagonists: A new therapeutic approach for Alzheimer disease [J]. Geratrics, 2004, 59(6) : 22-31.
  • 3李迎,曹树贵,梅兴国.气相色谱法测定盐酸美金刚片的含量和溶出度[J].中国药学杂志,2005,40(22):1743-1745. 被引量:12
  • 4FDA. Dissolution on methods database [ EB/OL ] . http :l/www. ac- cessdata, fda. gov/scripts/cder/ dissolution] dsp_SearchResults_Dissolu- t/ons, cfm,2002-06-14/2014-07-07.
  • 5Judit D, Istvan A. Evaluation of mathematical models describing durg release from lipophilic matrices [ J ]. Int J Pharm, 1996, 145 ( 1 ) : 61-64.
  • 6郑俊民.片剂包衣的工艺与原理[M].北京:中国医药科技出版社,2001.12-13.

二级参考文献22

  • 1Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate(NMDA) receptor antagonist-a review of preclinical data [J]. Neuropharmacology, 1999,38:735.
  • 2Suckow FR,Zhang FM, Collins DE, et al. Sensitive and selective liquid chromatographic assay of mementine in plasma with fluorescence detection after pre-column derivatization[J]. J Chromatogr B, 1999,729:217.
  • 3Freudenthaler S, Meineke I, Schreeb HK, et al. Influence of urine pH and urinary flow on the renal excretion of memantine [J]. Br J Clin Pharmacol, 1998,46: 541.
  • 4Nurnberg E, Seiller E, Ritsert S. Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof[P]. USP:5382601,1995-1-17.
  • 5FREUDENTHALER S,MEINEKE I,SCHREEB KH,et al.Influence of urine pH and urinary flow on the renal excretion of memantine[J].Br J Clin Pharmacol,1998,46 (6):541-546.
  • 6GAUTHIER S,WIRTH Y,MOBIUS HJ.Effects of memantine on behavioural symptoms in Alzheimer's disease patients:an analysis of the neuropsychiatric inventory (NPI) data of two randomised,controlled studies[J].Int J Geriatr Psychiatry,2005,20 (5):459 -464.
  • 7REISBERG B,FERRIS S,MOBIUS HJ,et al.Long-term treatment with the NMDA antagonist memantine:results of a 24-week,open-label extension study in moderately severe-to-severe Alzheimer's disease[J].Neurobiol Aging,2002,23 (1):S555.
  • 8PARSONS CG,DANYSZ W,QUACK G.Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist-a review of preclinical data[J].Neuropharmacology,1999,38(6):735 -767.
  • 9SONKUSARE SK,KAUL CL,RAMARAO P.Dementia of Alzheimer's disease and other neurodegenerative disorders-memantine,a new hope[J].Pharmacol Res,2005,51 (1):1-17.
  • 10PLOSKER GL,LYSENG-WILLIAMSON KA.Memantine:A pharmacoeconomic review of its use in moderate-to-severe Alzheimer's Disease[J].Pharmacoeconomics,2005,23 (2):193-206.

共引文献36

同被引文献63

引证文献6

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部